The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 237 of the 241 references it cites were found in a registry or an index.
Abstract
Objective: To develop clinical practice guidelines for the management of patients with primary aldosteronism. Participants: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee of the Endocrine Society, six additional experts, a methodologist, and a medical writer. The guideline was cosponsored by American Heart Association, American Association of Endocrine Surgeons, European Society of Endocrinology, European Society of Hypertension, International Association of Endocrine Surgeons, International Society of Endocrinology, International Society of Hypertension, Japan Endocrine Society, and The Japanese Society of Hypertension. The Task Force received no corporate funding or remuneration. Evidence: We searched for systematic reviews and primary studies to formulate the key treatment and prevention recommendations. We used the Grading of Recommendations, Assessment, Development, and Evaluation group criteria to describe both the quality of evidence and the strength of recommendations. We used “recommend” for strong recommendations and “suggest” for weak recommendations. Consensus Process: We achieved consensus by collecting the best available evidence and conducting one group meeting, several conference calls, and multiple e-mail communications. With the help of a medical writer, the Endocrine Society's Clinical Guidelines Subcommittee, Clinical Affairs Core Committee, and Council successfully reviewed the drafts prepared by the Task Force. We placed the version approved by the Clinical Guidelines Subcommittee and Clinical Affairs Core Committee on the Endocrine Society's website for comments by members. At each stage of review, the Task Force received written comments and incorporated necessary changes. Conclusions: For high-risk groups of hypertensive patients and those with hypokalemia, we recommend case detection of primary aldosteronism by determining the aldosterone-renin ratio under standard conditions and recommend that a commonly used confirmatory test should confirm/exclude the condition. We recommend that all patients with primary aldosteronism undergo adrenal computed tomography as the initial study in subtype testing and to exclude adrenocortical carcinoma. We recommend that an experienced radiologist should establish/exclude unilateral primary aldosteronism using bilateral adrenal venous sampling, and if confirmed, this should optimally be treated by laparoscopic adrenalectomy. We recommend that patients with bilateral adrenal hyperplasia or those unsuitable for surgery should be treated primarily with a mineralocorticoid receptor antagonist.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Algorithm for the detection, confirmation, subtype testing, and treatment of PA. a We recommend unilateral laparoscopic adrenalectomy for patients with documented unilateral PA (ie, APA or UAH) (1 ⎪ QQQE ). If a patient is unable or unwilling to undergo surgery, we recommend medical treatment including a MR antagonist (1 ⎪ QQQE ). If an ARR-positive patient is unwilling or unable to undergo further investigations, we similarly recommend medical treatment including an MR antagonist (1 ⎪ QQEE ). b Instead of proceeding directly to subtype classification, we recommend that patients with a positive ARR undergo one or more confirmatory tests to definitively confirm or exclude the diagnosis (1 ⎪ QQEE ). However, in the setting of spontaneous hypokalemia, undetectable renin, and PAC > 20 ng/dL (550 pmol/L), we suggest that there may be no need for further confirmatory testing (2 ⎪ QEEE ). c We recommend that when surgical treatment is feasible and desired by the patient, an experienced radiologist should use AVS to make the distinction between unilateral and bilateral adrenal disease (1 ⎪ QQQE ). Younger patients ( < age 35) with spontaneous hypokalemia, marked aldosterone excess, and unilateral adrenal lesions with radiological features consistent with a cortical adenoma on adrenal CT scan may not need AVS before proceeding to unilateral adrenalectomy (2 ⎪ QEEE ). [Adapted from J. W. Funder et al: Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab . 2008;93:3266-3281 (3), with permission. © Endocrine Society.]](https://figures.cochat.ai/paper-figures/aaade82f5c4b425bbdee69e74321806d/the-management-of-primary-aldosteronism-case-detection-diagnosis-and-treatment-figure-1.png)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most common types of secondary hypertension in adults are renal parenchymal disease, renovascular hypertension, primary aldosteronism, chronic sleep apnea, and substance/drug-induced.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [116]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A specific cause of secondary hypertension can be identified in 5%-10% of hypertensive patients (Table 11).”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [116]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [116]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypokalemia, which reduces aldosterone secretion, should be corrected with oral K+ supplements before testing.”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [289]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients with unilateral disease (50%; aldosterone-producing adenoma or, much less frequently, unilateral hyperplasia) respond to unilateral laparoscopic adrenalectomy with complete cure (≈50%) or improvement (≈50%) in BP control.”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [289]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation group, an international group with expertise in the development and implementation of evidence-based guidelines (2).”
MethodNational High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) · PEDIATRICS · doi:10.1542/peds.114.2.s2.555 · Cited by 6,938
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
(1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440420033005 · Cited by 3,777
(2003) · Journal of Hypertension · doi:10.1097/00004872-200311000-00002 · Cited by 2,672
Funder, J. W., Carey, R. M., Fardella, C., Gomez-Sanchez, C. E., Mantero, F., Stowasser, M., Young, W. F., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0104 · Cited by 1,554 · cited 3×
“The recommendations and suggestions made by the Task Force were subject to extensive consultation before being published in the Journal of Clinical Endocrinology and Metabolism in 2008 (3).”
MethodSelf-citationEvidence for an increased rate of cardiovascular events in patients with primary aldosteronism
Milliez, P., Girerd, X., Plouin, P.-F., Blacher, J., Safar, M. E., & Mourad, J.-J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.015 · Cited by 1,547 · cited 2×
“Several outcome studies also have provided evidence that PA patients are particularly at risk of cardiovascular/ renal complications, including arrhythmias, myocardial infarction, strokes, chronic kidney disease, and death, compared with age-, sex-, and BP-matched essential hypertensives (30, 33, 156).”
BackgroundResultA prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients
Rossi, G. P., Bernini, G., Caliumi, C., Desideri, G., Fabris, B., Ferri, C., Ganzaroli, C., Giacchetti, G., Letizia, C., Maccario, M., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.059 · Cited by 1,467 · cited 2×
“However, some groups have suggested that when clinicians administer a bolus injection of cosyntropin and sample the adrenal veins simultaneously, cosyntropin does not improve the diagnostic accuracy of AVS, and, in fact, cosyntropin may increase secretion from the nonadenomatous gland to a greater degree than from the…”
BackgroundSelf-citation
Research works printed but not linked: 3
- 15. Tucker RM, Labarthe DR. Frequency of surgical treatment for hypertensioninadultsattheMayoClinicfrom1973through1975. Mayo Clin Proc . 1977;52:549-545.
- 133. FardellaCE,PintoM,MossoL,Gómez-SánchezC,JalilJ,Montero J. Genetic study of patients with dexamethasone-suppressible aldosteronismwithoutthechimericCYP11B1/CYP11B2gene. J Clin Endocrinol Metab . 2001;86:4805-4807.
- 169. Jacobsen NE, Campbell JB, Hobart MG. Laparoscopic versus openadrenalectomyforsurgicaladrenaldisease. CanJUrol . 2003; 10:1995-1999.
Cited by
Items 201–300 of 1,002
Satoh, F., Ito, S., Itoh, H., Rakugi, H., Shibata, H., Ichihara, A., Omura, M., Takahashi, K., Okuda, Y., & Iijima, S. (2020) · Hypertension Research · doi:10.1038/s41440-020-00570-5 · Cited by 60
Self-citationUnilateral Primary Aldosteronism: Long-Term Disease Recurrence After Adrenalectomy
Tetti, M., Brüdgam, D., Burrello, J., Udager, A. M., Riester, A., Knösel, T., Beuschlein, F., Rainey, W. E., Reincke, M., & Williams, T. A. (2024) · Hypertension · doi:10.1161/hypertensionaha.123.22281 · Cited by 61
“Case detection of PA and subtype differentiation of unilateral from bilateral disease by unstimulated adrenal venous sampling (AVS) was performed using criteria reported in recent guidelines 3,4,36 implemented into local operational procedures.”
MethodSelf-citationAge-Related Cutoffs of Plasma Aldosterone/Renin Concentration for Primary Aldosteronism Screening
Ma, L., Song, Y., Mei, M., He, W., Hu, J., Cheng, Q., Tang, Z., Luo, T., Wang, Y., Zhen, Q., et al. (2018) · International Journal of Endocrinology · doi:10.1155/2018/8647026 · Cited by 59
“The aldosterone-renin ratio (ARR) is advocated as the most reliable tool for PA screening in high-risk groups of hypertensive patients [1].”
BackgroundMethodRossitto, G., Maiolino, G., Lerco, S., Ceolotto, G., Blackburn, G. J., Mary, S., Antonelli, G., Berton, C., Bisogni, V., Cesari, M., et al. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa205 · Cited by 64
“If patients were already treated, screening was performed after appropriate wash-out from agents affecting the renin–angiotensin–aldosterone system and switch to calcium channels blockers and/or doxazosin, as per guidelines, 13 unless contraindicated.”
BackgroundMethodO’Shea, P. M., O’Donoghue, D., Bashari, W., Senanayake, R., Joyce, M. B., Powlson, A. S., Browne, D., O’Sullivan, G. J., Cheow, H., Mendichovszky, I., et al. (2019) · Clinical Endocrinology · doi:10.1111/cen.13942 · Cited by 58
“PA was diagnosed according to Endocrine Society Guidelines.”
MethodZhou, Y., Zhang, M., Ke, S., & Liu, L. (2017) · BMC Endocrine Disorders · doi:10.1186/s12902-017-0209-z · Cited by 61
“, angiotensin II, plasma potassium concentration), and is not suppressed by sodium loading [1].”
BackgroundA Novel Method: Super-selective Adrenal Venous Sampling
Makita, K., Nishimoto, K., Kitamoto, K. K., Karashima, S., Seki, T., Yasuda, M., Matsui, S., Omura, M., & Nishikawa, T. (2017) · Journal of Visualized Experiments · doi:10.3791/55716 · Cited by 60
GENETICS IN ENDOCRINOLOGY: The expanding genetic horizon of primary aldosteronism
Monticone, S., Buffolo, F., Tetti, M., Veglio, F., Pasini, B., & Mulatero, P. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0946 · Cited by 60
Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using 68 Ga-Pentixafor
Ding, J., Tong, A., Zhang, Y., Wen, J., Zhang, H., Hacker, M., Huo, L., & Li, X. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.261964 · Cited by 57
“Identifying the functional distinctions between adrenal nodules remains challenging (3,4).”
BackgroundSomatic and inherited mutations in primary aldosteronism
Fernandes-Rosa, F. L., Boulkroun, S., & Zennaro, M. (2017) · Journal of Molecular Endocrinology · doi:10.1530/jme-17-0035 · Cited by 57
“The genetic diagnosis is usually made by Southern blot or long PCR, both techniques with high sensitivity and specificity (Funder et al. 2016).”
BackgroundMethodKitamoto, T., Omura, M., Suematsu, S., Saito, J., & Nishikawa, T. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001578 · Cited by 58
Strajina, V., Al‐Hilli, Z., Andrews, J. C., Bancos, I., Thompson, G. B., Farley, D. R., Lyden, M. L., Dy, B. M., Young, W. F., & McKenzie, T. J. (2017) · Surgery · doi:10.1016/j.surg.2017.10.012 · Cited by 56
Self-citationAldosterone and 18-Oxocortisol Coaccumulation in Aldosterone-Producing Lesions
Sugiura, Y., Takeo, E., Shimma, S., Yokota, M., Higashi, T., Seki, T., Mizuno, Y., Oya, M., Kosaka, T., Omura, M., et al. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11243 · Cited by 58
Genetic causes of primary aldosteronism
Seidel, E., Schewe, J., & Scholl, U. I. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0337-9 · Cited by 63
Schewe, J., Seidel, E., Forslund, S. K., Markó, L., Peters, J., Müller, D. N., Fahlke, C. M., Stölting, G., & Scholl, U. I. (2019) · Nature Communications · doi:10.1038/s41467-019-13033-4 · Cited by 57
Rossi, G. P., Ceolotto, G., Rossitto, G., Maiolino, G., Cesari, M., & Seccia, T. M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa080 · Cited by 56
Endocrine disorders in obstructive sleep apnoea syndrome: A bidirectional relationship
Akset, M., Poppe, K. G., Kleynen, P., Bold, I., & Bruyneel, M. (2022) · Clinical Endocrinology · doi:10.1111/cen.14685 · Cited by 64
“similar PA prevalence in OSA and the general population, there is no longer a need to screen for PA in OSA patients with hypertension, as formerly recommended by Endocrine Society in 2016.(35)”
BackgroundPrimary Aldosteronism and Resistant Hypertension: A Pathophysiological Insight
Bioletto, F., Bollati, M., Lopez, C., Arata, S., Procopio, M., Ponzetto, F., Ghigo, E., Maccario, M., & Parasiliti‐Caprino, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094803 · Cited by 63
“In fact, the pathophysiological mechanisms underlying the development of hypertension in patients with PA are persistent and sustained even during treatment with a conventional 3-drug combination regimen (which typically includes a diuretic, a CCB, and either an ACEi or an ARB); the driving mechanisms of sodium retent…”
BackgroundTreating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks
Mullen, N., Curneen, J. M. G., Donlon, P. T., Prakash, P., Bancos, I., Gurnell, M., & Dennedy, M. C. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad026 · Cited by 56
Primary Aldosteronism Screening Rates Differ with Sex, Race, and Comorbidities
Turcu, A. F., Nhan, W., Grigoryan, S., Zhang, L., Urban, C., Liu, H., Holevinski, L., & Zhao, L. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025952 · Cited by 56
“Among patients with hypertension included, we identified candidates for PA screening as patients who met at least one of the following criteria: (1) apparent resistant hypertension (defined by active hypertension while simultaneously taking ≥3 antihypertensive agents, or taking ≥4 antihypertensive agents); (2) hyperte…”
BackgroundPrevalence of Functioning Adrenal Incidentalomas: A Systematic Review and Meta-analysis
Sconfienza, E., Tetti, M., Forestiero, V., Veglio, F., Mulatero, P., & Monticone, S. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad044 · Cited by 61
Adrenal Venous Sampling for Assessment of Autonomous Cortisol Secretion
Ueland, G. Å., Methlie, P., Jøssang, D. E., Sagen, J. V., Viste, K., Thordarson, H. B., Heie, A., Grytaas, M. A., Løvås, K., Biermann, M., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01198 · Cited by 54
Zhang, H., Li, Q., Liu, X., Zhao, Z., He, H., Sun, F., Hong, Y., Zhou, X., Li, Y., Shen, R., et al. (2020) · Journal of Clinical Hypertension · doi:10.1111/jch.13960 · Cited by 55
Pofi, R., Prete, A., Thornton-Jones, V., Bryce, J., Ali, S. R., Faisal Ahmed, S., Balsamo, A., Baronio, F., Cannuccia, A., Guven, A., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz055 · Cited by 53
“26 respectively as recommended within the 192 Endocrine Society guidance (14); b) plasma renin activity values expressed as nmol/L/h (n=33) 193 were converted using a factor derived from a polyfit 3rd grade equation generated with MatLab 194 (version 2017, MathWorks® Inc.”
MethodIdentification of Somatic Mutations in CLCN2 in Aldosterone-Producing Adenomas
Rege, J., Nanba, K., Blinder, A., Plaska, S. W., Udager, A. M., Vats, P., Kumar‐Sinha, C., Giordano, T. J., Rainey, W. E., & Else, T. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa123 · Cited by 56
“Primary aldosteronism (PA) is defined as inappropriately elevated aldosterone production via renin-independent mechanisms [1].”
BackgroundMethodA flexible symbolic regression method for constructing interpretable clinical prediction models
Cava, W. L., Lee, P. C., Ajmal, I., Ding, X., Solanki, P., Cohen, J. B., Moore, J. H., & Herman, D. S. (2023) · npj Digital Medicine · doi:10.1038/s41746-023-00833-8 · Cited by 63
“PA appears to affect up to ~1% of US adults and it is highly treatable; unfortunately, it is under-screened for and under-diagnosed 39 – 44 .”
Primary Aldosteronism: KCNJ5 Mutations and Adrenocortical Cell Growth
Yang, Y., Gómez-Sánchez, C. E., Jaquin, D., Prada, E. T. A., Meyer, L. S., Knösel, T., Schneider, H., Beuschlein, F., Reincke, M., & Williams, T. A. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.13476 · Cited by 54
Self-citationGómez-Sánchez, C. E., Gómez-Sánchez, E. P., & Nishimoto, K. (2020) · Hormone and Metabolic Research · doi:10.1055/a-1139-2079 · Cited by 59
“Between 30–70 % of patients with hyperaldosteronism have bilateral ZG hyperplasia or idiopathic hyperaldosteronism as diagnosed by adrenal vein sampling [6, 8, 61, 62].”
BackgroundPrimary aldosteronism is a public health issue: challenges and opportunities
Libianto, R., Fuller, P. J., Young, M. J., & Yang, J. (2020) · Journal of Human Hypertension · doi:10.1038/s41371-020-0336-2 · Cited by 57
Plasma Steroid Profiling in Patients With Adrenal Incidentaloma
Berke, K., Constantinescu, G. A., Masjkur, J. R., Kimpel, O., Dischinger, U., Peitzsch, M., Kwapiszewska, A., Dobrowolski, P., Nölting, S., Reincke, M., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab751 · Cited by 56
Self-citationHypokalemic myopathy in primary aldosteronism: A case report
Wu, C.-F., Xin, J., Xin, M., Zou, H., Jing, L., Zhu, C., & Lei, W. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3864 · Cited by 52
“Aldosterone-producing adenoma and bilateral adrenal hyperplasia are the two most prevalent causes of primary aldosteronism (3).”
Familial hyperaldosteronism type III
Monticone, S., Tetti, M., Burrello, J., Buffolo, F., Giovanni, R. D., Veglio, F., Williams, T. A., & Mulatero, P. (2017) · Journal of Human Hypertension · doi:10.1038/jhh.2017.34 · Cited by 53
Genetic mechanisms of human hypertension and their implications for blood pressure physiology
Seidel, E., & Scholl, U. I. (2017) · Physiological Genomics · doi:10.1152/physiolgenomics.00032.2017 · Cited by 60
Baron, S., Amar, L., Faucon, A., Blanchard, A., Baffalie, L., Faucard, C., Travers, S. A. A., Pagny, J.-Y., Azizi, M., & Houillier, P. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001735 · Cited by 53
“Aldosterone secretion was considered to be nonsuppressible if the post-SIT PAC was higher than 139 pmol/l [7].”
BackgroundMethodInfluentialClassic and Nonclassic Apparent Mineralocorticoid Excess Syndrome
Carvajal, C. A., Tapia-Castillo, A., Vecchiola, A., Baudrand, R., & Fardella, C. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz315 · Cited by 59
Hypokalemia and the Prevalence of Primary Aldosteronism
Gruber, S., & Beuschlein, F. (2020) · Hormone and Metabolic Research · doi:10.1055/a-1134-4980 · Cited by 56
“These findings resulted in a change of clinical practice with the implementation of the ARR as the gold standard for PA screening and establishment of new screening indications beyond that of hypokalemia.”
BackgroundMethodResultInfluentialEvaluation and Management of Secondary Hypertension
Sarathy, H., Salman, L. A., Lee, C. S., & Cohen, J. B. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.11.004 · Cited by 64
Kobayashi, M., Pitt, B., Ferreira, J. P., Rossignol, P., Girerd, N., & Zannad, F. M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf225 · Cited by 53
Radiofrequency ablation compared with laparoscopic adrenalectomy for aldosterone-producing adenoma
Liu, S. Y., Chu, C. M., Kong, A. P. S., Wong, G. L., Chiu, P. W. Y., Chow, F. C. C., & Ng, E. K. W. (2016) · British journal of surgery · doi:10.1002/bjs.10219 · Cited by 52
Inflammation and Fibrosis in Perirenal Adipose Tissue of Patients With Aldosterone-Producing Adenoma
Wu, C., Zhang, H., Zhang, J., Xie, C., Fan, C., Zhang, H., Wu, P., Wei, Q., Tan, W., Xu, L., et al. (2018) · Endocrinology · doi:10.1210/en.2017-00651 · Cited by 52
“234 Wu et al Primary Aldosteronism: Adipose Tissue Alterations Endocrinology, January 2018, 159(1):227–237”
BackgroundInfluentialAdrenocortical Carcinoma with Hypercortisolism
Puglisi, S., Perotti, P., Pia, A. R., Reimondo, G., & Terzolo, M. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.02.003 · Cited by 52
“Screening for hyperaldosteronism by measuring of plasma aldosterone and plasma renin activity (PRA) (or direct renin concentration) is recommended in all hypertensive and/or hypokalemic patients with adrenal masses 15 .”
Samnani, S., Cenzer, I., Kline, G. A., Lee, S. J., Hundemer, G. L., McClurg, C., Pasieka, J. L., Boscardin, W. J., Ronksley, P. E., & Leung, A. A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad654 · Cited by 50
Satoh, M., Maruhashi, T., Yoshida, Y., & Shibata, H. (2019) · Hypertension Research · doi:10.1038/s41440-019-0244-4 · Cited by 51
Self-citationAlterations in endothelial nitric oxide synthase activity and their relevance to blood pressure
Suvorava, T., Metry, S., Pick, S., & Kojda, G. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115256 · Cited by 53
Faconti, L., Kulkarni, S., Delles, C., Kapil, V., Lewis, P., Glover, M., MacDonald, T. M., & Wilkinson, I. B. (2023) · Journal of Human Hypertension · doi:10.1038/s41371-023-00875-1 · Cited by 57
“From a methodological aspect, the lack of uniformity in diagnostic protocols and assay methods for measuring the ARR has also been associated with substantial variability in cut-off values (Table 3 [1]).”
BackgroundInfluentialPrevalence and Risk Factors for Secondary Hypertension in Young Adults
de Fréminville, J.-B., Gardini, M., Cremer, A., Camelli, S., Baron, S., Bobrie, G., Gosse, P., Boulestreau, R., Gebara, N., Doublet, J., et al. (2024) · Hypertension · doi:10.1161/hypertensionaha.124.22753 · Cited by 56
Hypertension: Overly important but under-controlled
van Kleef, M. E. A. M., & Spiering, W. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317709116 · Cited by 53
Itcho, K., Oki, K., Kobuke, K., Yoshii, Y., Ohno, H., Yoneda, M., & Hattori, N. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.08.019 · Cited by 61
“Primary aldosteronism (PA) is the most frequent cause of secondary hypertension associated with autonomous excess aldosterone production and secretion (Funder et al., 2016).”
BackgroundHealth-Related Quality of Life and Mental Health in Primary Aldosteronism: A Systematic Review
Velema, M. S., de Nooijer, A., Burgers, V. W. G., Hermus, A. R., Timmers, H. J. L. M., Lenders, J. W. M., Husson, O., & Deinum, J. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-121706 · Cited by 52
“Two prospective studies showed that untreated patients with APA [8] and untreated patients with BAH [7] reported lower mental and physical HRQoL than the general population on four domains of the SF-36: physical functioning, role limitations due to physical health problems, general health perceptions and vitality.”
BackgroundInfluentialSam, D., Kline, G. A., So, B., & Leung, A. A. C. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02089 · Cited by 49
Manolis, A. S., Manolis, T. A., Melita, H., & Manolis, A. S. (2019) · Current Hypertension Reports · doi:10.1007/s11906-019-0924-0 · Cited by 54
Guo, Z., Poglitsch, M., Cowley, D., Domenig, O., McWhinney, B. C., Ungerer, J. P. J., Wolley, M. J., & Stowasser, M. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.14871 · Cited by 50
“test for PA) in which the demonstration of ongoing aldosterone secretion in the face of suppression of Ang II achieved by captopril administration is regarded as diagnostic for PA.(7,46,51) Mulatero et al(10) reported that among 52 patients with raised ARR and PAC, although administration of fosinopril (20 mg/ day for…”
MethodSelf-citationVariability of Aldosterone Measurements During Adrenal Venous Sampling for Primary Aldosteronism
Yozamp, N. S., Hundemer, G. L., Moussa, M., Underhill, J., Fudim, T., Sacks, B. A., & Vaidya, A. (2020) · American Journal of Hypertension · doi:10.1093/ajh/hpaa151 · Cited by 51
Approach to the Patient with Primary Aldosteronism: Utility and Limitations of Adrenal Vein Sampling
Turcu, A. F., & Auchus, R. J. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa952 · Cited by 51
Teruyama, K., Naruse, M., Tsuiki, M., & Kobayashi, H. H. (2021) · Journal of Human Hypertension · doi:10.1038/s41371-020-00465-5 · Cited by 50
Corssmit, E. P. M., & Dekkers, O. M. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000528 · Cited by 59
Shah, S. S., Zhang, J., Gwini, S. M., Young, M. J., Fuller, P. J., & Yang, J. (2024) · Journal of Human Hypertension · doi:10.1038/s41371-023-00891-1 · Cited by 50
Rapid Screening of Primary Aldosteronism by a Novel Chemiluminescent Immunoassay
Morimoto, R., Ono, Y., Tezuka, Y., Kudo, M., Yamamoto, S., Arai, T., Gómez-Sánchez, C. E., Sasano, H., Ito, S., & Satoh, F. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.09078 · Cited by 49
Kobuke, K., Oki, K., Gómez-Sánchez, C. E., Gómez-Sánchez, E. P., Ohno, H., Itcho, K., Yoshii, Y., Yoneda, M., & Hattori, N. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.10205 · Cited by 50
Disordered CYP11B2 Expression in Primary Aldosteronism
Gómez-Sánchez, C. E., Kuppusamy, M., Reincke, M., & Williams, T. A. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-122238 · Cited by 49
“Primary aldosteronism (PA) is the most common form of secondary hypertension with a prevalence of 6–10 % of patients with primary hypertension [1] and is associated with a significant increase in morbidity and mortality [2, 3].”
BackgroundSelf-citationARMC5 mutations in familial and sporadic primary bilateral macronodular adrenal hyperplasia
Yu, L., Zhang, J., Guo, X., Chen, X., He, Z., & He, Q. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191602 · Cited by 51
Update in adrenal venous sampling for primary aldosteronism
Rossi, G. P. (2018) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000407 · Cited by 50
Morera, J., & Reznik, Y. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0704 · Cited by 53
Personalized Medicine and the Treatment of Hypertension
Melville, S., & Byrd, J. B. (2019) · Current Hypertension Reports · doi:10.1007/s11906-019-0921-3 · Cited by 54
O’Toole, S. M., Sze, W.-C., Chung, T., Akker, S. A., Druce, M. R., Waterhouse, M., Pitkin, S. L., Dawnay, A., Sahdev, A., Matson, M. B., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa519 · Cited by 49
Tabarin, A., Espiard, S., Deutschbein, T., Amar, L., Vezzossi, D., Dalmazi, G. D., Reznik, Y., Young, J., Desailloud, R., Goichot, B., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00062-2 · Cited by 51
Arruda, M., Cavalari, E. M. R., de Paula, M. P., de Morais, F. F. C., Bilro, G. F., Coelho, M. C. A., de Morais, N. A. D. O. E. S., Choeri, D., Moraes, A. B., & Neto, L. V. (2017) · Journal of Human Hypertension · doi:10.1038/s41371-017-0011-4 · Cited by 50
Simone, G., Anceschi, U., Tuderti, G., Misuraca, L., Celia, A., CONCILIO, B. D., Costantini, M., Stigliano, A., Minisola, F., Ferriero, M. C., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.07.030 · Cited by 47
Ono, Y., Yamazaki, Y., Omata, K., Else, T., Tomlins, S. A., Rhayem, Y., Williams, T. A., Reincke, M., Carling, T., Monticone, S., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz235 · Cited by 48
Self-citationCeolotto, G., Antonelli, G., Maiolino, G., Cesari, M., Rossitto, G., Bisogni, V., Plebani, M., & Rossi, G. P. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.09415 · Cited by 47
Cornu, E., Steichen, O., Nogueira‐Silva, L., Küpers, E. M., Pagny, J.-Y., Grataloup, C., Baron, S., Zinzindohoué, F., Plouin, P., & Amar, L. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07214 · Cited by 50
“This strategy is also proposed in the recently published guidelines for patients with hypokalemia.(16) SIT remains important for the diagnosis of PA: in this study, 44% of the 16 patients with normal basal but nonsuppressible aldosterone levels had lateralized PA.”
MethodPrimary Aldosteronism: Mutations, Mechanisms, Prevalence, and Public Health
Funder, J. W. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.12935 · Cited by 50
Self-citationKitamoto, T., Kitamoto, K. K., Omura, M., Takiguchi, T., Tsurutani, Y., Kubo, H., Yamazaki, Y., Sasano, H., Saito, J., & Nishikawa, T. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.14341 · Cited by 47
“0 after ACTH stimulation.(5,6,21) Although some experts, including the Writing Committee members of the Japan Endocrine Society guidelines, recommended the use of the criteria of (aldosterone) adrenal vein ≥1400 ng/dL after ACTH stimulation in the hypersecretion of aldosterone,(21,23) no prospective study validating t…”
BackgroundInfluentialShariq, O. A., Bancos, I., Cronin, P. A., Farley, D. R., Richards, M. L., Thompson, G. B., Young, W. F., & McKenzie, T. J. (2017) · Surgery · doi:10.1016/j.surg.2017.07.034 · Cited by 47
Self-citationCastro, M. A., Guevara, M. I., Gutiérrez, M. C., Ramírez, P. A. P., Gimeno, P. G., Hanzu, F. A., & Lamas, C. (2020) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2020.03.002 · Cited by 50
Wang, K., Hu, J., Yang, J., Song, Y., Fuller, P. J., Hashimura, H., He, W., Feng, Z., Cheng, Q., Du, Z., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa282 · Cited by 45
Alam, S., Kandasamy, D., Goyal, A., Vishnubhatla, S., Singh, S., Karthikeyan, G., & Khadgawat, R. (2021) · Clinical Endocrinology · doi:10.1111/cen.14409 · Cited by 45
Fernández-Argüeso, M., Corrales, E. P., Rojano, N. B., Cano, A. M. G., Mendiguchía, L. J., & Castro, M. A. (2021) · Endocrine · doi:10.1007/s12020-021-02704-2 · Cited by 47
Ceccato, F., Antonelli, G., Frigo, A. C., Regazzo, D., Plebani, M., Boscaro, M., & Scaroni, C. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0644-8 · Cited by 44
“Primary aldosteronism and pheochromocytoma were excluded in all subjects [16, 17].”
BackgroundPrimary aldosteronism in pregnancy
Forestiero, V., Sconfienza, E., Mulatero, P., & Monticone, S. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09729-6 · Cited by 46
“In fact, although hypokalemia is not a sensitive tool for PA screening in the general population [17], serum potassium levels have found to be low in the majority of described cases of PA during pregnancy [13, 58].”
BackgroundMethodInfluentialThe SPARTACUS Trial: Controversies and Unresolved Issues
Beuschlein, F., Mulatero, P., Asbach, E., Monticone, S., Catena, C., Sechi, L. A., & Stowasser, M. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-120524 · Cited by 46
“In conclusion, the SPARTACUS trial conveys the strong message that in patients with PA ADX based on CT diagnosis has a similar outcome compared with ADX based on AVS findings, thereby challenging the current Endocrine Society Guideline [11].”
BackgroundResultSelf-citationPrimary Aldosteronism and Obstructive Sleep Apnea: Is This A Bidirectional Relationship?
Prejbisz, A., Kołodziejczyk‐Kruk, S., Lenders, J. W. M., & Januszewicz, A. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-122887 · Cited by 45
“This supports the recommendation of the Endocrine Society guideline to screen for PA in hypertensive patients with OSA [9].”
BackgroundMethodTapia-Castillo, A., Baudrand, R., Vaidya, A., Campino, C., Allende, F. A., Valdivia, C. P., Vecchiola, A., Lagos, C. F., Fuentes, C., Solari, S., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01197 · Cited by 50
“b-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, and diuretics were placed on amlodipine or doxazosin for$4weeks for BP control due to the neutral effect on the renin-angiotensin system (6).”
BackgroundAdrenal venous sampling: cosyntropin stimulation or not?
Deinum, J., Groenewoud, H., van der Wilt, G. J., Lenzini, L., & Rossi, G. P. (2019) · European Journal of Endocrinology · doi:10.1530/eje-18-0844 · Cited by 46
Sun, N., Meyer, L. S., Feuchtinger, A., Kunzke, T., Knösel, T., Reincke, M., Walch, A. K., & Williams, T. A. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.14041 · Cited by 46
“The study was performed on 16 adrenals removed by unilateral adrenalectomy from patients diagnosed with unilateral PA according to the diagnostic flowchart recommended by the Endocrine Society Guideline with an adrenal venous sampling protocol described previously.(27,28) Samples were selected from surgical cases from…”
MethodSelf-citationMeng, Z., Dai, Z., Huang, K., Xu, C., Zhang, Y.-G., Zheng, H., & Liu, T.-Z. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00121 · Cited by 46
Targeted Metabolomics as a Tool in Discriminating Endocrine From Primary Hypertension
Erlic, Z., Reel, P. S., Reel, S., Amar, L., Pecori, A., Larsen, C. K., Tetti, M., Pamporaki, C., Prehn, C. P., Adamski, J., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa954 · Cited by 47
“Since the diagnostic performance of the currently recommended selection criteria for EHT screening—such as young age at diagnosis or high grade or resistant hypertension (14, 15, 29)—is not available, a direct comparison with current Figure 4.”
BackgroundMethodSelf-citationCerebro-Cardiovascular Risk, Target Organ Damage, and Treatment Outcomes in Primary Aldosteronism
Lin, X., Ullah, M. H. E., Xiong, W., Xu, F., Shan, S., Lei, L.-M., Yuan, L., & Liu, J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.798364 · Cited by 45
Brown, J. M., Auchus, R. J., Honzel, B., Luther, J. M., Yozamp, N. S., & Vaidya, A. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac049 · Cited by 46
“Increasingly, older immunoassay technologies have been supplanted by liquid chromatography–tandem mass spectrometry (LC-MS/MS) for clinical measurement of aldosterone concentration; however, clinical guideline recommendations [22], and most clinical practice patterns, still generally rely on relatively arbitrary thres…”
BackgroundMethodInfluentialSun, F., Liu, X., Zhang, H., Zhou, X., Zhao, Z., He, H., Yan, Z., Li, Y., Li, Q., Li, Y., et al. (2022) · Hypertension Research · doi:10.1038/s41440-022-01034-8 · Cited by 43
“an expert consensus statement on the use of AVS for PA subtyping [5], successful sampling was determined by a high selectivity index (SI) (cortisol in the adrenal vein/ cortisol ≥2 inferior vena cava without adrenocorticotropic hormone simulation).”
BackgroundMethodInfluentialDing, J., Li, X., Liu, S., Gao, Y., Zheng, G., Hacker, M., Zhang, Y., Tong, A., & Huo, L. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.266061 · Cited by 45
“Adrenal CT and adrenal venous sampling (AVS) are recommended for PA subtyping by the Endo-crine Society practice guidelines ( 4 ).”
Rossi, E., Perazzoli, F., Negro, A., & Magnani, A. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001384 · Cited by 46
“Indeed, at least 60% of the primary aldosteronism patients are normokalemic [1].”
BackgroundHu, Y., Zhang, J., Liu, W., & Su, X. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz293 · Cited by 46
MANAGEMENT OF ENDOCRINE DISEASE: The role of surgical adrenalectomy in primary aldosteronism
Hundemer, G. L., & Vaidya, A. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0863 · Cited by 44
Diagnostic Accuracy of CT Texture Analysis in Adrenal Masses: A Systematic Review
Crimì, F., Quaia, E., Cabrelle, G., Zanon, C., Pepe, A., Regazzo, D., Tizianel, I., Scaroni, C., & Ceccato, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020637 · Cited by 48
“Overt endocrine secretion (glucocorticoids, mineralocorticoids, and catecholamines, characterising, respectively, Cushing’s syndrome, primary aldosteronism, and pheochromocytoma) should be ruled out in all patients with AI by the measurement of serum cortisol after 1 mg dexamethasone (the overnight suppression test),…”
BackgroundDeLozier, O. M., Dream, S. Y., Findling, J. W., Carroll, T. B., Evans, D. B., & Wang, T. S. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab698 · Cited by 42
Loh, H. H., Lim, Q. H., Chai, C.-S., Goh, S. L., Lim, L., Yee, A. H. A., & Sukor, N. (2022) · Journal of Sleep Research · doi:10.1111/jsr.13726 · Cited by 45
“The 2016 Endocrine Society Clinical Practice Guidelines for PA recommend screening for PA in individuals with hypertension and OSA (Funder et al., 2016).”
BackgroundSubtyping of Primary Aldosteronism by Adrenal Venous Sampling
Rossi, G. P., Battistel, M., Seccia, T. M., Rossi, F. B., & Rossitto, G. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf007 · Cited by 44
Primary aldosteronism: key characteristics at diagnosis: a trend toward milder forms
Heinrich, D. A., Adolf, C., Rump, L. C., Quack, I., Quinkler, M. O., Hahner, S., Januszewicz, A., Seufert, J., Willenberg, H. S., Nirschl, N., et al. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0978 · Cited by 46
Self-citationDecision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options
Puglisi, S., Perotti, P., Cosentini, D., Roca, E., Basile, V., Berruti, A., & Terzolo, M. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1510325 · Cited by 43
Metadata
- Authors
- Funder, J. W., Carey, R. M., Mantero, F., Murad, M. H., Reincke, M., Shibata, H., Stowasser, M., & Young, W. F.
- Affiliations
- Hudson Institute of Medical Research (AU)
- University of Virginia Health System (US)
- University of Padua (IT)
- Mayo Clinic (US)
- Klinikum of the Ludwig-Maximilians-University of Munich (M.R.), 80366 München, Bavaria, Germany
- Oita University (JP)
- The University of Queensland (AU)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2016-05-01
- Volume
- 101
- Issue
- 5
- Pages
- 1889-1916
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2290633895
- Semantic Scholar
- 36716f26ebd3b8e468f352d9132208c41e5688c0
- Cited by
- 2,925
- References
- 241
- Citations by year
- 2026: 236 · 2025: 397 · 2024: 315 · 2023: 329 · 2022: 329 · 2021: 315 · 2020: 293 · 2019: 238 · 2018: 200 · 2017: 188 · 2016: 72
- FWCI
- 233.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- primary aldosteronism, case finding, aldosterone-renin ratio, adrenal computed tomography, adrenal vein sampling, laparoscopic adrenalectomy, bilateral adrenal hyperplasia, mineralocorticoid receptor antagonists, hypertension, hypokalemia
- MeSH terms
- Adrenal Glands, Adrenalectomy, Aldosterone, Mineralocorticoid Receptor Antagonists, Humans, Hyperaldosteronism, Renin, Evidence-Based Medicine, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.